In a meta-analysis of randomized trials in autism spectrum disorders, oxytocin did not significantly reduce restricted and repetitive behaviors versus placebo.
In plain wordsIn a pooled analysis of trials in autism, oxytocin did not significantly reduce repetitive behaviors compared with placebo.
- Peptide
- Oxytocin
- Outcome
- No significant changeRestricted and repetitive behaviors (RRB) rating scales
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Autism core symptoms · Mental health and mood
- Studied dose
- Dose not stated
Measurements
- SMD
- 0.23
- oxytocin versus placebo, RRB
- 95% CI lower
- −0.01
- oxytocin versus placebo, RRB
- 95% CI upper
- 0.47
- oxytocin versus placebo, RRB
Source sentences
oxytocin, omega-3 fatty acids, selective serotonin reuptake inhibitors (SSRI), and methylphenidate did not demonstrate significant benefit in reducing RRB compared to placebo (oxytocin: SMD = 0.23, 95% CI = -0.01 to 0.47, z = 1.85, p = .06
1 context sentence(design, population, supporting numbers)
We searched PubMed, Embase, and CENTRAL to identify all double-blind, randomized, placebo-controlled trials that examined the efficacy of pharmacological agents in the treatment of ASD and measured RRB as an outcome.